Related Experiment Video
Updated: Mar 29, 2026
08:12
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
6.1K
The Evolving Role for Repeat Molecular Testing in Metastatic Colorectal Cancer
Nicholas D Kendsersky1, Mariah R Erlick1, Emerson Y Chen1
1Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA.
Cancers
|March 28, 2026
Summary
Sequential biomarker testing in metastatic colorectal cancer (mCRC) aids in identifying resistance mechanisms and guiding subsequent treatments. Repeat testing post-progression is crucial for optimizing therapy and clinical trial selection.
Area of Science:
- Oncology
- Genomics
- Translational Medicine
Background:
- Next-generation sequencing (NGS) has transformed metastatic colorectal cancer (mCRC) treatment by enabling targeted and immune therapies.
- Current guidelines (NCCN, ASCO) recommend initial biomarker testing (RAS, BRAF, HER2, MSI/MMR) for therapeutic eligibility.
- Broader molecular profiling for tumor-agnostic therapies (TMB, NTRK, RET fusions) is encouraged in advanced solid tumors.
Purpose of the Study:
- To review the advantages and disadvantages of sequential biomarker testing in mCRC patients during disease progression.
- To highlight the role of repeat biomarker analysis in understanding adaptive resistance mechanisms.
- To inform the development of unified guidelines for sequential testing in mCRC.
Main Methods:
- Comprehensive literature review on sequential biomarker testing in mCRC.
- Analysis of studies evaluating biomarker changes at disease progression.
- Evaluation of current NCCN and ASCO recommendations.
Main Results:
- NGS-driven therapies have improved outcomes in mCRC.
- Repeat biomarker testing can reveal resistance mechanisms and guide subsequent treatment decisions.
- Lack of unified guidelines for sequential biomarker testing presents a challenge.
Conclusions:
- Sequential biomarker testing is essential for managing adaptive resistance in mCRC.
- Repeat molecular profiling can optimize subsequent therapy selection and clinical trial enrollment.
- Standardized guidelines are needed to facilitate consistent implementation of sequential biomarker testing.
Keywords:
ctDNAmetastatic colorectal cancernext-generation-sequencingprecision medicinesequential NGSMore Related Videos
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
68
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
01:20Mismatch Repair
7.0K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
7.0K